BSX vs EDIT · P/E 20, rev $16.75B vs rev $32.3M
Boston Scientific Corp (BSX) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
Boston Scientific Corp (BSX) is a medical devices company listed on US.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported BSX revenue for 2024-12-31 was $16.75B. Net income was $1.85B. Revenue was up 17.6% from 2023-12-31 to 2024-12-31. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
BSX currently screens at market cap $71.81B and trailing P/E 20.2. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the BSX and EDIT stock pages for the full models.
Not investment advice.